FindTrial
Sign In

A study for Jie-du granule on advanced liver cancer

A study for safety and effect of Jie-du granule in the treatment of advanced liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005606
Enrollment
Unknown
Registered
2014-12-04
Start date
2015-01-01
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepetocelluler carcinoma

Interventions

TCM group :Jie-du granule
controlled group:sorafenib

Sponsors

Department of integrative oncology, Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female, age older than 18yr; 2. Diagnosed with hepatocellular carcinoma according to the Guideline of Primary Liver Cancer published by the Ministry of Health of P. R. China; 3. Stage is C according to the BCLC staging classification; 4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2.

Exclusion criteria

Exclusion criteria: 1. Received chemotherapy or radiotherapy or local therapies such as TACE, RF within 4 weeks; 2. Serum total bilirubin higher than 3 times of upper limit of normal value or ascites; 3. Serum creatinine higher than 2 times of upper limit of normal value; 4. Gastrointestinal hemorrhage within 4 weeks; 5. Have other malignant tumors; 6. Severe infection; 7. Pregnancy.

Design outcomes

Primary

MeasureTime frame
1 year survival;—

Secondary

MeasureTime frame
Overall survival;Objective remission rate;safety index;Improvement of symptoms;—

Contacts

Public ContactChang-quan Ling

Department of integrative oncology, Changhai Hospital

zhaixfch@163.com+86 02131161950

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026